BELLEVILLE, ON,
June 27, 2013 /PRNewswire/ - Bioniche
Life Sciences Inc. (TSX: BNC) (ASX: BNC) today announced that it
will be hosting a:
Conference Call & Audio Webcast
Tuesday, July 9, 2013
6:00 p.m. ET
Company representatives will provide an update on GMP validation
of its Animal Health and Food Safety Vaccine Manufacturing Centre
in Belleville, Ontario.
To participate in the conference call from North America, call (888) 231-8191 (conference
ID: 13113047).
To participate in the conference call from Australia, call 1-800-287-011 (conference ID:
13113047).
A listen-only audio webcast will be available at:
http://event.on24.com/r.htm?e=653147&s=1&k=562F01AE2A898EFCF88998DC1602D956
A replay of the conference call will be available until
July 16, 2013 at midnight by calling
1-855-859-2056 (passcode: 13113047).
The webcast will be available for replay using the above link
until July 8, 2014.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based,
technology-driven Canadian biopharmaceutical company focused on the
discovery, development, manufacturing, and marketing of proprietary
and innovative products for human and animal health markets
worldwide. The fully-integrated company employs more than 200
skilled personnel and has three operating divisions: Human Health,
Animal Health, and Food Safety. The Company's primary goal is to
develop and commercialize products that advance human or animal
health and increase shareholder value.
For more information, please visit
www.Bioniche.com.
Except for historical information, this news
release may contain forward-looking statements that reflect the
Company's current expectation regarding future events. These
forward-looking statements involve risk and uncertainties, which
may cause, but are not limited to, changing market conditions, the
successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties
related to the regulatory approval process, and other risks
detailed from time to time in the Company's ongoing quarterly and
annual reporting.
SOURCE Bioniche Life Sciences Inc.